These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
759 related articles for article (PubMed ID: 23255218)
1. BET bromodomain-targeting compounds reactivate HIV from latency via a Tat-independent mechanism. Boehm D; Calvanese V; Dar RD; Xing S; Schroeder S; Martins L; Aull K; Li PC; Planelles V; Bradner JE; Zhou MM; Siliciano RF; Weinberger L; Verdin E; Ott M Cell Cycle; 2013 Feb; 12(3):452-62. PubMed ID: 23255218 [TBL] [Abstract][Full Text] [Related]
2. The BET bromodomain inhibitor JQ1 activates HIV latency through antagonizing Brd4 inhibition of Tat-transactivation. Li Z; Guo J; Wu Y; Zhou Q Nucleic Acids Res; 2013 Jan; 41(1):277-87. PubMed ID: 23087374 [TBL] [Abstract][Full Text] [Related]
3. BET-Inhibitors Disrupt Rad21-Dependent Conformational Control of KSHV Latency. Chen HS; De Leo A; Wang Z; Kerekovic A; Hills R; Lieberman PM PLoS Pathog; 2017 Jan; 13(1):e1006100. PubMed ID: 28107481 [TBL] [Abstract][Full Text] [Related]
4. The KAT5-Acetyl-Histone4-Brd4 axis silences HIV-1 transcription and promotes viral latency. Li Z; Mbonye U; Feng Z; Wang X; Gao X; Karn J; Zhou Q PLoS Pathog; 2018 Apr; 14(4):e1007012. PubMed ID: 29684085 [TBL] [Abstract][Full Text] [Related]
5. A New Quinoline BRD4 Inhibitor Targets a Distinct Latent HIV-1 Reservoir for Reactivation from Other "Shock" Drugs. Abner E; Stoszko M; Zeng L; Chen HC; Izquierdo-Bouldstridge A; Konuma T; Zorita E; Fanunza E; Zhang Q; Mahmoudi T; Zhou MM; Filion GJ; Jordan A J Virol; 2018 May; 92(10):. PubMed ID: 29343578 [TBL] [Abstract][Full Text] [Related]
6. Reactivation of latent HIV-1 by inhibition of BRD4. Zhu J; Gaiha GD; John SP; Pertel T; Chin CR; Gao G; Qu H; Walker BD; Elledge SJ; Brass AL Cell Rep; 2012 Oct; 2(4):807-16. PubMed ID: 23041316 [TBL] [Abstract][Full Text] [Related]
7. HIV latency reversing agents act through Tat post translational modifications. Khoury G; Mota TM; Li S; Tumpach C; Lee MY; Jacobson J; Harty L; Anderson JL; Lewin SR; Purcell DFJ Retrovirology; 2018 May; 15(1):36. PubMed ID: 29751762 [TBL] [Abstract][Full Text] [Related]
8. A new BET on the control of HIV latency. Karn J Cell Cycle; 2013 Feb; 12(4):545-6. PubMed ID: 23370386 [No Abstract] [Full Text] [Related]
9. Bromodomain and extra-terminal (BET) bromodomain inhibition activate transcription via transient release of positive transcription elongation factor b (P-TEFb) from 7SK small nuclear ribonucleoprotein. Bartholomeeusen K; Xiang Y; Fujinaga K; Peterlin BM J Biol Chem; 2012 Oct; 287(43):36609-16. PubMed ID: 22952229 [TBL] [Abstract][Full Text] [Related]
10. P-TEFb as a target to reactivate latent HIV: two Brds are now in hand. Rice AP Cell Cycle; 2013 Feb; 12(3):392-3. PubMed ID: 23324342 [TBL] [Abstract][Full Text] [Related]
11. A Natural Product from Polygonum cuspidatum Sieb. Et Zucc. Promotes Tat-Dependent HIV Latency Reversal through Triggering P-TEFb's Release from 7SK snRNP. Wang C; Yang S; Lu H; You H; Ni M; Shan W; Lin T; Gao X; Chen H; Zhou Q; Xue Y PLoS One; 2015; 10(11):e0142739. PubMed ID: 26569506 [TBL] [Abstract][Full Text] [Related]
12. The Short Isoform of BRD4 Promotes HIV-1 Latency by Engaging Repressive SWI/SNF Chromatin-Remodeling Complexes. Conrad RJ; Fozouni P; Thomas S; Sy H; Zhang Q; Zhou MM; Ott M Mol Cell; 2017 Sep; 67(6):1001-1012.e6. PubMed ID: 28844864 [TBL] [Abstract][Full Text] [Related]
13. Phosphorylation of CDK9 at Ser175 enhances HIV transcription and is a marker of activated P-TEFb in CD4(+) T lymphocytes. Mbonye UR; Gokulrangan G; Datt M; Dobrowolski C; Cooper M; Chance MR; Karn J PLoS Pathog; 2013; 9(5):e1003338. PubMed ID: 23658523 [TBL] [Abstract][Full Text] [Related]
14. An In-Depth Comparison of Latency-Reversing Agent Combinations in Various In Vitro and Ex Vivo HIV-1 Latency Models Identified Bryostatin-1+JQ1 and Ingenol-B+JQ1 to Potently Reactivate Viral Gene Expression. Darcis G; Kula A; Bouchat S; Fujinaga K; Corazza F; Ait-Ammar A; Delacourt N; Melard A; Kabeya K; Vanhulle C; Van Driessche B; Gatot JS; Cherrier T; Pianowski LF; Gama L; Schwartz C; Vila J; Burny A; Clumeck N; Moutschen M; De Wit S; Peterlin BM; Rouzioux C; Rohr O; Van Lint C PLoS Pathog; 2015 Jul; 11(7):e1005063. PubMed ID: 26225566 [TBL] [Abstract][Full Text] [Related]
15. Targeting BRD4 proteins suppresses the growth of NSCLC through downregulation of eIF4E expression. Gao Z; Yuan T; Zhou X; Ni P; Sun G; Li P; Cheng Z; Wang X Cancer Biol Ther; 2018 May; 19(5):407-415. PubMed ID: 29333921 [TBL] [Abstract][Full Text] [Related]
16. UHRF1 Suppresses HIV-1 Transcription and Promotes HIV-1 Latency by Competing with p-TEFb for Ubiquitination-Proteasomal Degradation of Tat. Liang T; Zhang Q; Wu Z; Chen P; Huang Y; Liu S; Li L mBio; 2021 Aug; 12(4):e0162521. PubMed ID: 34465029 [TBL] [Abstract][Full Text] [Related]
17. The mTOR Complex Controls HIV Latency. Besnard E; Hakre S; Kampmann M; Lim HW; Hosmane NN; Martin A; Bassik MC; Verschueren E; Battivelli E; Chan J; Svensson JP; Gramatica A; Conrad RJ; Ott M; Greene WC; Krogan NJ; Siliciano RF; Weissman JS; Verdin E Cell Host Microbe; 2016 Dec; 20(6):785-797. PubMed ID: 27978436 [TBL] [Abstract][Full Text] [Related]
18. The double bromodomain-containing chromatin adaptor Brd4 and transcriptional regulation. Wu SY; Chiang CM J Biol Chem; 2007 May; 282(18):13141-5. PubMed ID: 17329240 [TBL] [Abstract][Full Text] [Related]
19. Flow Cytometric Analysis of HIV-1 Transcriptional Activity in Response to shRNA Knockdown in A2 and A72 J-Lat Cell Lines. Boehm D; Ott M Bio Protoc; 2017 Jun; 7(11):. PubMed ID: 29082287 [TBL] [Abstract][Full Text] [Related]
20. BET bromodomain proteins are required for glioblastoma cell proliferation. Pastori C; Daniel M; Penas C; Volmar CH; Johnstone AL; Brothers SP; Graham RM; Allen B; Sarkaria JN; Komotar RJ; Wahlestedt C; Ayad NG Epigenetics; 2014 Apr; 9(4):611-20. PubMed ID: 24496381 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]